Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
Melanocortin receptor ligands
No-Receipt date
2021-04989 - 24/12/2021
No-Filing date
20210800049 - 24/12/2021
No-Granting date
8000896 - 21/10/2022
No-EPO application date
-
No-EPO granting date
-
Gazette No-Publication date of application
4/2022 - 09/05/2022
Gazette No-Publication date of granted patent
10/2022 - 09/11/2022
Expiration date
11/07/2031
Kind of title
Supplementary Protection Certificate for Medicinal Products
Legal status
VALID
Priorities
-
Active Substance of Supplementary Certificates
ΣΕΤΜΕΛΑΝΟΤΙΔΗ (ΕΜΠΟΡΙΚΗ ΟΝΟΜΑΣΙΑ: IMCIVREE)
IPC Classification
Related Documents
Related Titles
Type
Master title
Related title
[SPC]
20120401347
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
1848467
IPSEN PHARMA
70 RUE BALARD
PARIS
75015
FRANCE
Inventors
Code
Firstname
Surname
1011065
DONG, ZHENG XIN
1011066
MOREAU, JACQUES-PIERRE
Representatives
Code
Firstname
Surname
Address
Town
Zip
3713
ALKISTIS-EIRINI
MALAMI
VISSARIONOS 3
ATHINA (ATTIKIS)
10672
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
9219
ALKISTIS-EIRINI
MALAMI
VISSARIONOS 3
ATHINA (ATTIKIS)
10672
GREECE
Owners History
Date
Description
Comments
Data before modification
Data after modification
18/12/2025
Αλλαγή Έδρας (7g805)
ΑΡ.ΠΡΩΤ. 31835/2025 (ΑΡ.ΥΠΟΘ. 13548/2025) ΠΛΗΡΕΞ. ΔΙΚΗΓΟΡΟΣ ΧΡΙΣΤΙΝΑ ΚΙΟΡΤΣΗ (ΑΛΛΑΓΗ ΕΔΡΑΣ)
425965 IPSEN PHARMA 65 Quai Georges Gorse ΓΑΛΛΙΑ 92100 Boulogne-Billancourt
1848467 IPSEN PHARMA 70 rue Balard ΓΑΛΛΙΑ PARIS
Title Instruments
Date
Operation
Descreption
12/22/2022 12:00:00 AM
Διάφορες Μεταβολές (70004)
ΑΡΣΗ & ΑΝΤΙΚ./ΣΤΑΣΗ ΠΛΗΡΕΞ./ΑΝΤΙΚΛΗΤΟΥ.
Payments history
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).